12th-14th September, 2016

London

Day One
Tuesday 13th September 2016

Day Two
Wednesday 14th September 2016

07:45
Registration & Breakfast

Advancing Biomarker Discovery & Development

08:20
Chairman’s Opening Remarks & Keynote Presentation

  • Samuel Agus Chief Specialist, Medical Affairs, Neurology, Lundbeck

Synopsis

If Precision Medicine in Dementia Prevention is Our Destination, How do We Get There?

  • Addressing challenges and opportunities in neurodegenerative research
  • Discussing strategies to tackling neurodegeneration going forward
  • An insight into the industry in 2025: Can we achieve precision medicine in neuroscience disease research?

08:30
Developing Novel, Accurate Clinical Diagnostic & Disease Progression Biomarkers

  • Garry Honey Head of Biomarkers & Clinical Imaging, Roche

Synopsis

  • Evaluating strategies for identifying features of amyloid accumulation in the brain with simple diagnostic tools
  • Understanding how to best identify measures that will track with clinical function, particularly with response of therapy, to produce accurate clinical readouts
  • Readdressing programmes for predictive biomarker development for preventative treatments: what markers and when to start diagnostic testing?

09:00
Translational Perspectives on Biomarker Discovery & Development in AD

Synopsis

  • Analysing interaction between pre-clinical and clinical research in biomarker development
  • Examining the timing of the interaction – what to do when in pre-clinical and clinical development
  • Tackling translational challenges in biomarker development in AD

09:30
If Precision Medicine in Dementia Prevention in Our Destination, How do We Get There?

  • Craig Ritchie Professor of the Psychiatry of Aging, University of Edinburgh & Project Co-ordinator, EPAD

Synopsis

More info to follow.

10:00
Panel Discussion: Achieving the Goal of Cost Effective, Non-Invasive Biomarkers

  • Alastair Brown Head of Pharmacology, Heptares
  • Garry Honey Head of Biomarkers & Clinical Imaging, Roche
  • Harald Hampel Professor, AXA Research Fund & UPMC Chair, Sorbonne Universities, Pierre & Marie Curie University
  • Helle Sickmann Clinical Pharmacology Scientist, Lundbeck

Synopsis

  • Critical analysis of the field: Current endeavours in developing biomarkers for neurodegeneration from target engagement to disease progression
  • How do we develop biomarkers in the most efficient way possible?
  • Analysing the long term contribution to clinical trials: Should surrogate biomarkers still be our primary focus for clinical readouts
  • Debating regulation: What should we regard as a valid surrogate biomarker to best show impact on neurodegenerative progression?
  • Improving standardisation in the validation and development of biomarkers for neurodegeneration

10.45
Speed Networking & Morning Refreshments

Translational Modelling in Neurodegenerative Research

11:30
Advancing Human iPSC Models for Translational Research

Synopsis

  • Harnessing iPSC derived neurons to help elucidate pathological development of neurodegeneration
  • Understanding how to best apply iPSC modelling to advance drug discovery and development efforts
  • Utilising iPSC modelling to advance the concept of personalised medicine in neurodegenerative diseases
  • Debating the value of iPSC models to translational neurodegenerative research

12:00
The Conundrum of Modifying Neurodegeneration in a Mouse: Optimizing Pre-Clinical Approaches to Improve Probability of Clinical Success

  • Susan Browne Director, CNS Discovery, Teva Pharmaceuticals

Synopsis

  • Addressing the validity of animal assays in neurodegeneration research: Are we entrenched in their use?
  • Developmental goals for the optimum use of animal approaches to reduce the risk of clinical failure
  • Harnessing advances in gene editing to expand the pre-clinical toolbox
  • Importance of being early: Building on our knowledge of fundamental disease biology to modify disease etiology

12:30
Non-Human Primate Models of Motor Symptoms, Cognitive Dysfunction & Molecular Pathology of Parkinson’s Disease

Synopsis

  • Addressing non-human primate models of PD based upon over-expression of alpha-synuclein, focally in the substantia nigra, through viral vector-delivered alphasynuclein to produce degeneration of dopaminergic neurons
  • Reviewing the pathology, behavioural and imaging finding in MPTP compared to alpha-synuclein models in non-human primates
  • Discussing how best to employ both in the search for novel therapeutics for PD, whether they be symptomatic or disease-modifying

12:50
Panel Discussion: Debating Pre-Clincal Translational Modelling in Neurodegeneration

  • Fabio Blandini  Director, Center for Research in Neurodegenerative Diseases,  IRCCS C. Mondino National Neurological Institute
  • Susan Browne Director, CNS Discovery, Teva Pharmaceuticals

Synopsis

  • Critical review of current pre-clinical models and understanding the questions we want these models to answer
  • What are appropriate models of neurodegeneration?
  • How do we develop the ideal translational model?
  • Can we build models that reproduce early progression of disease?
  • Identifying triggers of disease to better inform disease modelling
  • Analysing the strengths and weaknesses of different pre-clinical modelling systems to advance pre-clinical translation
  • Delineating differences in modelling between academia and industry: What we can we learn from one another?
  • Can we model the multifactorial pathology of neurodegenerative diseases?

Updates on Tau: The Therapeutic Strategy for Neurodegeneration?

13:30
Networking Lunch

14:30
[18F]MK-6240, A Novel Tau PET Tracer: From Discovery to Clinical Evaluation

  • Cyrille Sur Executive Director & Neuroscience Imaging Lead, Merck

Synopsis

  • Reviewing the pharmacology profile of [18F]MK-6240
  • Pre-clinical characterisation and differentiation from AV-1451
  • Addressing the clinical evaluation of [18F] MK-6240

15:00
Reviewing Tau as a Therapeutic Strategy in Neurodegenerative Diseases

  • Suchira Bose Principal Research Scientist, Eli Lilly & Company

Synopsis

  • Latest advances in the treatment of tauopathies and potential applications for wider neurodegenerative therapeutic strategies
  • Understanding the interplay between tau and amyloid to advance the translational development of therapeutic interventions and potential combination therapies

15:30
Afternoon Refreshments

Evolving Science in Neurodegeneration

16:00
Breakout Roundtable Discussion: Evolving Science in Neurodegeneration

  • Kate Bingham Managing Partner, SV Life Sciences
  • Tobias Hartmann Professor, Experimental Neurology, Saarland University
  • Tiago Outeiro Professor & Director, Department of Neurodegeneration and Neurorestoration, University Medical Center Gottingen
  • David Reynolds Chief Scientific Officer, Alzheimer’s Research UK
  • Daniel Michaelson Professor of Neurobiology, Tel Aviv University

Synopsis

With the R&D endeavours of the past 20 years failing to culminate in the development of effective therapies against neurodegeneration, we take a look towards the future at how the field is shifting its R&D focus.

This session will focus on devising solutions that cannot be obtained in presentation format, and will give you actionable takeaways to build a more holistic understanding of the field. Access the critical information that is only obtainable through frank and open discussion around crucial topics in the field. Shape the debate around the following topics:

    • Science & Strategy in Translational Neurodegenerative Research
      David Reynolds, Chief Scientific Officer, Alzheimer’s Research UK
    • Identifying Molecular Markers of Alzheimer’s Disease
      Daniel Michaelson, Professor of Neurobiology, Tel Aviv University
      Tobias Hartmann, Professor, Experimental Neurology, Saarland University
    • What are the most promising novel targets for neurodegeneration?
      Tiago Outeiro, Professor & Director, Department of Neurodegeneration and Neurorestoration, University Medical Center Gottingen
    • How do we best build, develop and invest in neurodegenerative drug portfolios?
      Kate Bingham, Managing Partner, SV Life Sciences

17:15
Chair’s Closing Remarks

  • Samuel Agus Chief Specialist, Medical Affairs, Neurology, Lundbeck

17:20
Close of Day One